{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:35:42Z","timestamp":1785882942050,"version":"3.56.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1097\/mou.0b013e328356ac20","type":"journal-article","created":{"date-parts":[[2012,7,21]],"date-time":"2012-07-21T13:48:34Z","timestamp":1342878514000},"page":"415-420","source":"Crossref","is-referenced-by-count":15,"title":["Predictive factors for recurrence progression and cancer specific survival in high-risk bladder cancer"],"prefix":"10.1097","volume":"22","author":[{"given":"Oscar","family":"Rodr\u00edguez Faba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Palou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210206","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.juro.2011.07.076","article-title":"A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group.","volume":"186","author":"Brausi","year":"2011","journal-title":"J Urol"},{"key":"R2-12-20210206","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"R5-12-20210206","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","article-title":"Female Gender and Carcinoma In Situ in the Prostatic Urethra Are Prognostic Factors for Recurrence, Progression, and Disease-Specific Mortality in T1G3 Bladder Cancer Patients Treated With Bacillus Calmette-Guerin.","volume":"62","author":"Palou","year":"2012","journal-title":"Eur Urol"},{"key":"R6-12-20210206","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.juro.2006.11.090","article-title":"Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer.","volume":"177","author":"Raj","year":"2007","journal-title":"J Urol"},{"key":"R7-12-20210206","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2007.10.006","article-title":"Prognostic factors in patients with nonmuscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials.","volume":"53","author":"Fernandez-Gomez","year":"2008","journal-title":"Eur Urol"},{"key":"R8-12-20210206","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"R9-12-20210206","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.eururo.2011.05.033","article-title":"The EORTC tables overestimate the risk of recurrence and progression in patients with nonmuscle-invasive bladder cancer treated with bacillus Calmette-Guerin: external validation of the EORTC risk tables.","volume":"60","author":"Fernandez-Gomez","year":"2011","journal-title":"Eur Urol"},{"key":"R10-12-20210206","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jnci\/93.7.538","article-title":"Gender- and smoking-related bladder cancer risk.","volume":"93","author":"Castelao","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"R11-12-20210206","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0090-4295(00)00523-9","article-title":"Gender differences in stage-adjusted bladder cancer survival.","volume":"55","author":"Mungan","year":"2000","journal-title":"Urology"},{"key":"R12-12-20210206","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00345-011-0709-9","article-title":"Impact of gender on bladder cancer incidence, staging, and prognosis.","volume":"29","author":"Fajkovic","year":"2011","journal-title":"World J Urol"},{"key":"R13-12-20210206","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0022-5347(05)65469-9","article-title":"Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer.","volume":"167","author":"Saint","year":"2002","journal-title":"J Urol"},{"key":"R14-12-20210206","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3109\/03009734.2011.650797","article-title":"Urothelial bladder carcinoma in young patients is characterized by a relatively good prognosis.","volume":"117","author":"Poletajew","year":"2012","journal-title":"Ups J Med Sci"},{"key":"R15-12-20210206","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0302-2838(03)00048-4","article-title":"Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guerin (BCG) immunotherapy exist. analysis of a quarter century of literature.","volume":"43","author":"Saint","year":"2003","journal-title":"Eur Urol"},{"key":"R16-12-20210206","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1023\/A:1014444601158","article-title":"Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guerin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ.","volume":"33","author":"Takashi","year":"2002","journal-title":"Int Urol Nephrol"},{"key":"R17-12-20210206","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27mg in superficial bladder cancer.","volume":"89","author":"Martinez-Pineiro","year":"2002","journal-title":"BJU Int"},{"key":"R18-12-20210206","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0022-5347(05)00973-0","article-title":"The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy.","volume":"175","author":"Joudi","year":"2006","journal-title":"J Urol"},{"key":"R19-12-20210206","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-5347(05)67975-X","article-title":"Multivariate analysis of the prognostic factors of primary superficial bladder cancer.","volume":"163","author":"Millan-Rodriguez","year":"2000","journal-title":"J Urol"},{"key":"R20-12-20210206","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/j.1442-2042.2007.01890.x","article-title":"Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter A long-term analysis of 132 patients.","volume":"14","author":"Denzinger","year":"2007","journal-title":"Int J Urol"},{"key":"R21-12-20210206","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.juro.2010.03.022","article-title":"Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors.","volume":"184","author":"Alkhateeb","year":"2010","journal-title":"J Urol"},{"key":"R22-12-20210206","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0022-5347(05)67974-8","article-title":"Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results.","volume":"163","author":"Losa","year":"2000","journal-title":"J Urol"},{"key":"R23-12-20210206","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0022-5347(17)40575-1","article-title":"Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression.","volume":"141","author":"Herr","year":"1989","journal-title":"J Urol"},{"key":"R24-12-20210206","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0022-5347(05)67280-1","article-title":"Primary superficial bladder cancer risk groups according to progression, mortality and recurrence.","volume":"164","author":"Millan-Rodriguez","year":"2000","journal-title":"J Urol"},{"key":"R25-12-20210206","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0022-5347(01)64825-0","article-title":"Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation.","volume":"157","author":"Ovesen","year":"1997","journal-title":"J Urol"},{"key":"R26-12-20210206","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0090-4295(01)01603-X","article-title":"Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience.","volume":"59","author":"Pansadoro","year":"2002","journal-title":"Urology"},{"key":"R27-12-20210206","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1464-410X.2010.09572.x","article-title":"Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guerin treatment.","volume":"107","author":"Kakiashvili","year":"2011","journal-title":"BJU Int"},{"key":"R28-12-20210206","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"R29-12-20210206","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0090-4295(99)80481-6","article-title":"In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guerin therapy without previous transurethral resection of the prostate.","volume":"47","author":"Palou","year":"1996","journal-title":"Urology"},{"key":"R30-12-20210206","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S0022-5347(01)66762-4","article-title":"The prostate involvement as prognostic factor in patients with superficial bladder tumors.","volume":"154","author":"Solsona","year":"1995","journal-title":"J Urol"},{"key":"R31-12-20210206","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0022-5347(01)66338-9","article-title":"Extravesical involvement in patients with bladder carcinoma in situ: biological and therapy implications.","volume":"155","author":"Solsona","year":"1996","journal-title":"J Urol"},{"key":"R32-12-20210206","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-5347(05)67281-3","article-title":"The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer.","volume":"164","author":"Solsona","year":"2000","journal-title":"J Urol"},{"key":"R33-12-20210206","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0302-2838(02)00068-4","article-title":"Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies.","volume":"41","author":"Brausi","year":"2002","journal-title":"Eur Urol"},{"key":"R34-12-20210206","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2005.04.013","article-title":"Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1abc) in BCG-treated and BCG-nontreated patients.","volume":"48","author":"Orsola","year":"2005","journal-title":"Eur Urol"},{"issue":"Suppl 2","key":"R35-12-20210206","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1038\/modpathol.2009.1","article-title":"Staging and reporting of urothelial carcinoma of the urinary bladder.","volume":"22","author":"Cheng","year":"2009","journal-title":"Mod Pathol"},{"key":"R36-12-20210206","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/PAS.0b013e31823dafd3","article-title":"Pan CC: Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.","volume":"36","author":"Chang","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"R37-12-20210206","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.eururo.2011.10.026","article-title":"A new and highly prognostic system to discern T1 bladder cancer substage.","volume":"61","author":"van Rhijn","year":"2012","journal-title":"Eur Urol"},{"key":"R38-12-20210206","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/01.mou.0000240311.08701.55","article-title":"Lymphovascular invasion as a prognostic tool for advanced bladder cancer.","volume":"16","author":"Algaba","year":"2006","journal-title":"Curr Opin Urol"},{"key":"R39-12-20210206","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1016\/j.juro.2009.08.083","article-title":"Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer.","volume":"182","author":"Cho","year":"2009","journal-title":"J Urol"},{"key":"R40-12-20210206","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1464-410X.2008.08011.x","article-title":"The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer.","volume":"103","author":"Streeper","year":"2009","journal-title":"BJU Int"},{"key":"R41-12-20210206","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1464-410X.2010.09635.x","article-title":"Longitudinal evaluation of the concordance and prognostic value of lymphovascular invasion in transurethral resection and radical cystectomy specimens.","volume":"107","author":"Resnick","year":"2011","journal-title":"BJU Int"},{"key":"R42-12-20210206","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/j.ajpath.2012.01.023","article-title":"Cathepsin e, maspin, plk1, and survivin are promising prognostic protein markers for progression in nonmuscle invasive bladder cancer.","volume":"180","author":"Fristrup","year":"2012","journal-title":"Am J Pathol"},{"key":"R43-12-20210206","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s13277-010-0033-9","article-title":"Galectin-3 expression is associated with bladder cancer progression and clinical outcome.","volume":"31","author":"Canesin","year":"2010","journal-title":"Tumour Biol"},{"key":"R45-12-20210206","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.eururo.2011.04.020","article-title":"Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guerin response in patients with T1G3 high-risk bladder tumours.","volume":"60","author":"Agundez","year":"2011","journal-title":"Eur Urol"}],"container-title":["Current Opinion in Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOU.0b013e328356ac20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T04:09:07Z","timestamp":1620965347000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042307-201209000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mou.0b013e328356ac20","relation":{},"ISSN":["0963-0643"],"issn-type":[{"value":"0963-0643","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}